Farmers & Merchants Bank of Long Beach Declares Second-Quarter Cash Dividend Payment of $28 Per Share
LONG BEACH, Calif.--(BUSINESS WIRE)--Farmers & Merchants Bank of Long Beach (OTCQX: FMBL) today announced that its board of directors has approved the Bank's regular quarterly cash dividend of $28 per share on the Bank's common stock.
The quarterly dividend is payable on June 30, 2025, to shareholders of record as of June 13, 2025.
The declaration represents F&M's 532nd dividend payment. F&M has paid a dividend each year to shareholders since 1916, and the value of F&M's quarterly dividend has never decreased.
About Farmers & Merchants Bank of Long Beach
Founded in Long Beach in 1907 by C.J. Walker, Farmers & Merchants Bank provides white-glove service to clients at 27 branches from San Clemente to Santa Barbara, as well as through its Online and Mobile Banking platforms. The Bank offers commercial and small business banking, business loan programs, home loans, and a robust offering of consumer retail banking products, including checking, savings and youth accounts. Farmers & Merchants Bank is a California state-chartered bank with deposits insured by the Federal Deposit Insurance Corporation (Member FDIC) and an Equal Housing Lender. For more information about F&M, please visit the website, www.fmb.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
China: US needs to ‘stop spreading disinformation,' correct ‘wrongful actions'
China said on Tuesday that the United States needs to 'stop spreading disinformation' and correct 'wrongful actions' as the trade tensions between the two countries continue. China's foreign ministry spokesperson Lin Jian claimed the U.S. 'falsely accuses and smears' China and that Washington has taken 'extreme suppression' measures. He listed 'chip export controls, blocking EDA sales and announcing plans to revoke Chinese students' visas' as actions that have 'seriously disrupted the consensus and hurt China's legitimate rights and interests.' 'China firmly opposes them and has lodged strong protests with the US,' Lin wrote in a Tuesday post on the social media platform X. Treasury Department Secretary Scott Bessent said on Sunday that President Trump and Chinese President Xi Jinping will likely talk 'soon' — a conversation that will include discussing critical minerals. 'I am confident that when President Trump and party Chairman Xi have a call, that this will be ironed out,' Bessent said during his Sunday appearance on CBS's 'Face the Nation.' 'But the fact that they are withholding some of the products that they agreed to release during our agreement — maybe it's a glitch in the Chinese system, maybe it's intentional.' The world's two biggest economies have accused each other in recent days of violating the terms of the trade agreement struck during the meetings in Geneva last month. Trump hammered China on Friday, arguing that Beijing violated the terms of the agreement. 'Two weeks ago China was in grave economic danger! The very high Tariffs I set made it virtually impossible for China to TRADE into the United States marketplace which is, by far, number one in the World. We went, in effect, COLD TURKEY with China, and it was devastating for them. Many factories closed and there was, to put it mildly, 'civil unrest.' I saw what was happening and didn't like it, for them, not for us,' the president wrote on Truth Social. 'I made a FAST DEAL with China in order to save them from what I thought was going to be a very bad situation, and I didn't want to see that happen,' the commander-in-chief added. China fired back on Monday, saying that Washington was in breach of the trade agreement, citing the guidance on chip export controls, the pause of sales of chip design software to China and the revocation of F-1 student visas of Chinese students in the U.S. After the May talks in Switzerland, the Trump administration brought down the tariffs on Chinese imports from 145 percent to 30 percent. China lowered its duties on U.S. goods from 125 percent to 10 percent. Lin, the foreign ministry spokesperson, added on Tuesday that pressure and 'coercion are not the right way to engage China.' 'We urge the US to respect the facts, stop spreading disinformation, correct its wrongful actions, and act to uphold the consensus reached between the two sides,' the spokesperson added. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
Minaurum Announces Exercise of Option to Acquire Lone Mountain CRD Project in Nevada's Battle Mountain-Eureka Trend
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2025) - Minaurum Gold Inc. (TSXV: MGG) (OTCQX: MMRGF) ("Minaurum" or "the Company") is pleased to announce that, further to its news release dated October 2, 2024, it has provided the required notice to Nevada Zinc Corp. ("Nevada Zinc") to exercise its option (the "Option") to acquire a 100% registered and beneficial interest in the Lone Mountain carbonate replacement deposit ("CRD") project (the "Acquisition") located on the Battle Mountain-Eureka Trend in Nevada, USA ("Lone Mountain" or the "Project"). The Company is acquiring the Project pursuant to an option agreement between the Company and Nevada Zinc dated July 24, 2024, as amended on October 22, 2024 and December 24, 2024. Nevada Zinc completed a Preliminary Economic Assessment of the viability of potentially mining the zinc mineralization at the Project in June 2019 (NI 43-101 Preliminary Economic Assessment and Technical Report, Peimen Ling & Associates Limited, June 27, 2019 or see Nevada Zinc news release dated June 27, 2019 (the "PEA"). In accordance with the disclosure in the PEA, the Project is a brownfields project with a historic inferred mineral resource estimate of 3,257,000 tonnes grading 7.57% zinc and 0.70% lead. Select drilling highlights include 118.87 m of 9.58% Zn and 0.74% Pb (hole LM-15- 27); and 24.7 m grading 23.06% Zn (hole NLM-17-08). The PEA also demonstrated a 35% after tax internal rate of return ("IRR"). See below for further details on the Mineral Resource Estimate Report and the PEA. "Lone Mountain looks a lot like neighbouring historical silver-lead-zinc CRDs, such as Eureka next door or Cortez up the road, both of which have been found to have a significant Carlin Gold overprint," said Dr. Peter Megaw, Co-founder and Exploration Advisor to Minaurum. "Historical drilling was tightly focused on near-surface high-grade zinc oxides and did not seek that kind of gold mineralization or the polymetallic CRD sulphide potential that should lie beneath." "We are pleased to acquire Lone Mountain, an advanced project with robust economics that we believe could host significant silver and gold mineralization at depth," stated Darrell Rader, President & CEO of Minaurum. "As we advance our flagship Alamos silver project toward a maiden resource in 2025, we're strategically positioning Lone Mountain as the next catalyst for value creation in Minaurum's portfolio." Acquisition Terms In consideration of the Acquisition, the Company will: issue Nevada Zinc a number of common shares of the Company (the "Payment Shares") having an aggregate value of $1,000,000 based on the 10-day volume weighted average trading price of the common shares on the TSX Venture Exchange ("TSXV") for the 10 trading days immediately preceding the date of issuance; and pay Nevada Zinc a cash fee in the amount of $100,000. The completion of the Acquisition, including the issuance of the Payment Shares to Nevada Zinc, is subject to customary closing conditions, including, without limitation, approval of the TSXV. The Payment Shares will be subject to: (a) a four-month and one day statutory hold period, in accordance with applicable securities laws; and (b) a contractual restriction on transfer pursuant to which Nevada Zinc may not sell more than 500,000 Payment Shares per week after the expiry of the statutory hold period. Further information regarding Lone Mountain is disclosed in the Company's news release dated October 2, 2024 with key highlights described below. Lone Mountain CRD Project – Battle Mountain Eureka Trend, Nevada, USALone Mountain is a high-grade CRD project comprised of a single patented mining claim and 203 unpatented mining claims that cover 1,850 hectares. The Project lies 28 kms northwest of the historic Eureka Mining District, which anchors one end of the Battle Mountain-Eureka trend in Nevada, USA (Figure 1). The region supports an active mining workforce with significant resources for mineral exploration, mine development, and mine operations. Major mines in the region include Barrick Gold's Goldstrike and Carlin mines, Nevada Gold Mines, Pine Valley mine, Cortez Hills mine, McEwen Mining's Gold Bar mine and i80's Ruby Hill project, amongst others. Figure 1. Location of Lone Mountain CRD Project. Note position adjacent to Eureka Mining District on the Battle Mountain - Eureka trend. Click image to view an enhanced version of this graphic, please visit: Follow us and stay updated:YouTube: @minaurumgoldLinkedIn: to our email list at Minaurum Gold Inc. (TSXV: MGG) (OTCQX: MMRGF) (FSE: 78M) is an Americas-focused explorer concentrating on the high-grade 100% owned, production-permitted Alamos silver project in southern Sonora Mexico and the Lone Mountain CRD Project in Nevada. Minaurum is managed by one of the strongest technical and finance teams and will continue its founders' legacy of creating shareholder value by acquiring and developing a pipeline of Tier-One precious-and base metal projects. ON BEHALF OF THE BOARD "Darrell A. Rader" Darrell A. RaderPresident and CEO For more information, please contact:Sunny Pannu – Investor Relations and Corporate Development Manager(778) 330 0994 or via email at pannu@ The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this news release. ___________________________________________________________________________ 1570– 200 Burrard StreetTelephone 1 778 330-0994Vancouver, BC V6C info@ Cautionary Note Regarding Forward-Looking Information This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. "Forward-looking information" includes, but is not limited to, statements with respect to activities, events or developments that the Company expects or anticipates will or may occur in the future. Generally, but not always, forward-looking information and statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. Forward-looking information in this news release relating to the Company include, among other things, statements relating to the completion of the Acquisition, the receipt of TSXV approval for the completion of the Acquisition, and the issuance of the Payment Shares and the payment of the cash fee to Nevada Zinc in consideration of the Acquisition. In making the forward-looking information in this release, Minaurum has applied certain factors and assumptions that are based on Minaurum's current beliefs as well as assumptions made by and information currently available to Minaurum. including, without limitation, assumptions that the Company will proceed with completion of the Acquisition, that the Company will be able to issue the Payment Shares and make the cash payment as necessary to complete the Acquisition as anticipated and that the Company will receive TSXV approval for the completion of the Acquisition. Although Minaurum considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking information in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking information, including but not limited to risks associated with the following: the Company may not complete the Acquisition, on the terms and conditions disclosed, or at all; the Company may not be able to make the share or cash payments necessary to complete the Acquisition; the Company may not receive TSXV approval for the Acquisition; changes in governmental regulations; compliance with applicable laws and regulations; reliance on key personnel; title matters; conflicts of interest; environmental laws and regulations and associated risks, including climate change legislation; land reclamation requirements; changes in government policies; volatility of the Company's share price; infrastructure risks; fluctuations in demand for, and prices of metals; fluctuations in foreign currency exchange rates; unanticipated costs; and going concern risk. Readers are cautioned not to place undue reliance on forward-looking information. Minaurum does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by law. To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
Perimeter Announces Closing of Prospectus Offering
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO and DALLAS, June 3, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that it has completed its previously announced prospectus offering (the "Offering") of units of the Company (the "Units") and pre-funded units of the Company. The Offering was completed on a reasonable "best efforts" agency basis pursuant to an agency agreement (the "Agency Agreement") dated May 29, 2025 between the Company and A.G.P. Canada Investments ULC (the "Agent"). Pursuant to the Offering, the Company has issued an aggregate of 10,432,801 Units at a price of $0.30 per Unit (the "Offering Price") for aggregate gross proceeds of $3,129,840. Each Unit is comprised of one common share in the capital of the Company (each a "Common Share") and one Common Share purchase warrant (each a "Warrant"). Each Warrant entitles the holder to acquire an additional Common Share for a period of 60 months, at an exercise price of $0.35. Pursuant to the terms of the Agency Agreement, the Agent was entitled to receive a cash fee equal to 7.0% of the gross proceeds raised under the Offering, and compensation options equal to 5.0% of the aggregate number of Units issued under the Offering (the "Compensation Options"), with a reduced cash commission of 3.5% and Compensation Options equal to 2.5% payable in respect of Units sold to certain purchasers on a president's list. In addition, the Agent will receive no cash commission or Compensation Options with respect to sales to certain insiders of the Company. Each Compensation Option entitles the Agent to buy one Common Share at the same price as the price per Unit under the Offering. The Compensation Options are exercisable until that date which is 36 months following the closing date. The Company intends to use the net proceeds from the Offering to continue the commercialization of its technology, establish clinical evidence and continue product development. The Company also intends to use the net proceeds for working capital and other general corporate purposes. The Company may close additional tranches of the Offering for total gross proceeds of up to $15,000,000 (inclusive of the initial closing). The Offering was completed by way of a short form prospectus dated May 29, 2025 (the "Prospectus"). The Prospectus and the Agency Agreement are available on SEDAR+ at and contain important detailed information about the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the "1933 Act") and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the 1933 Act, and applicable state securities laws. Social Capital, a control person of the Company purchased a total of 115,217 Units under the Offering. The placement to such person constituted a "related party transaction" within the meaning of TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61- 101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the placement as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101). The Company has not filed a material change report more than 21 days before the expected closing of the Offering as the details of the Offering and the participants thereof were only finalized shortly before the closing of the Offering. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, statements regarding the use of proceeds from the Offering and the closing of additional tranches, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Annual Information Form for the year ended December 31, 2024, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. Contacts Stephen KilmerInvestor RelationsDirect: 647-872-4849Email: skilmer@ Adrian MendesChief Executive OfficerToll-free: 888-988-7465 (PINK)Email: investors@ SOURCE Perimeter Medical Imaging AI Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
